Clinical Trial Results:
Randomized Phase II AGO-Study comparing combined liposomal doxorubicin (Myocet) and gemcitabine (Gemzar) with liposomal doxorubicin (Myocet) monotherapy in platinum-refractory and platinum-resistant epithelial cancer of the ovary, fallopian tube, and the peritoneum
Summary
|
|
EudraCT number |
2008-008746-20 |
Trial protocol |
AT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
22 Jul 2023
|
First version publication date |
22 Jul 2023
|
Other versions |
|
Summary report(s) |
AGO 10 - Randomized Phase II in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube, and the Peritoneum |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.